SC
RXRX icon

Swan Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Swan Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$244 – 541
2025
Q3 		$244 Sell
50
-65
-57% -$341 ﹤0.01% 454
2025
Q2 		$582 Hold
115
– – ﹤0.01% 406
2025
Q1 		$608 Hold
115
– – ﹤0.01% 316
2024
Q4 		$777 Buy
+115
New +$773 ﹤0.01% 297

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Swan Capital's RXRX Position: Q4 2025 in Review

Swan Capital sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 50 shares — an estimated $244 sold.

Swan Capital first reported a position in RXRX in Q4 2024 and held it in 4 quarters. The position peaked at $777 in Q4 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Swan Capital reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Swan Capital sold 50 Recursion Pharmaceuticals shares in Q4 2025, an estimated $244.
  • Swan Capital first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Swan Capital's Recursion Pharmaceuticals position peaked at $777 in Q4 2024.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Swan Capital's 13F filing for Q4 2025, filed 12 Feb 2026.